Diadema Partners LP Apellis Pharmaceuticals, Inc. Transaction History
Diadema Partners LP
- $383 Billion
- Q1 2025
A detailed history of Diadema Partners LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 100,000 shares of APLS stock, worth $1.83 Million. This represents 1.37% of its overall portfolio holdings.
Number of Shares
100,000Holding current value
$1.83 Million% of portfolio
1.37%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$225 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$224 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$218 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$185 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$176 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.01B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...